.jpg?w=340&itok=fIjwgnRv "IPT discussed in technical publications."){kind=icon}
Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Strategies for building greater DE&I in Rare Disease trials
This article describes some of the systemic factors that produce barriers at various stages of the rare disease drug development process, as well as identifies strategies to improve diversity in these trials
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
-
As clinical trials face a hiring crunch, here’s how research organisations can pivot
Helen Yeardley, Senior Vice President, Global Clinical Operations, discusses how ICON is adapting to the global shortage of Clinical Research Associates in the industry.
-
The significant increase in demand for Clinical Research Associates (CRAs)
Helen Yeardley, Senior Vice President, Clinical Operations, offers her insights on the role that a Clinical Trial Associate (CRA) plays in the clinical trial process.
-
Pivotal time for CROs': ICON CEO Cutler on changing APAC trial trends
Steve Cutler and Atsushi Ogawa are interviewed in SCRIP where they discuss the increased opportunity for decentralised trials, in addition to the challenges and opportunities for clinical trials in Asia Pacific.
-
Trial blazing
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
January/February PharmaTimes
-
Historical Controls in Rare Disease drug development: Using RWE to overcome key challenges
The following article will explore the advantages of using HCs, as well as several considerations for their effective use, including scientific methodology and regulatory
-
Life sciences sector remains strong in Ireland despite challenges
Brendan Brennan outlines the importance of collaboration between industry and academia in this article from the Irish Times Life Sciences special report.
2022 The Irish Times DAC
-
.jpg?w=545&itok=S2qJPLkh "IPT discussed in technical publications.")
Turning an ocean of data into actionable wisdom to support optimal site identification
Travis Caudill, VP Feasibility & Clinical Informatics, offers his insights on how advancements in AI can help the pharmaceutical industry identify the best sites for their clinical trials through the harnessing of Big Data.
Innovations in Pharmaceutical Technology, December 2022, pages 24-25. Samedan Ltd
-
Life sciences industry an active player in pandemic response
Rose Kidd outlines the role ICON played in the global response to the COVID-19 pandemic in the Irish Times Life Sciences special report.
2022 The Irish Times DAC
